
Sophie Lanzkron

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3773560/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Acceptable, hopeful, and useful: development and mixed-method evaluation of an educational tool about reproductive options for people with sickle cell disease or trait. Journal of Assisted Reproduction and Genetics, 2022, 39, 183-193.	2.5	8
2	Liver Transplant in Hemoglobin SC Disease and Autoimmune Hepatitis: A Case Report. Experimental and Clinical Transplantation, 2022, , .	0.5	1
3	GRNDaD: big data and sickle cell disease. Blood Advances, 2022, 6, 1088-1088.	5.2	4
4	Diminished ovarian reserve in young women with sickle cell anemia. Blood, 2022, 139, 1111-1115.	1.4	17
5	Health Care Utilization by Adolescent/Young Adult Patients With Sickle Cell Disease in Delaware. Cureus, 2022, 14, e22700.	0.5	0
6	The Montreal cognitive assessment as a cognitive screening tool in sickle cell disease: Associations with clinically significant cognitive domains. British Journal of Haematology, 2022, , .	2.5	7
7	Pain without gain: steroids and sickle crisis. Blood, 2022, 139, 3678-3679.	1.4	3
8	Sickle Cell Disease. Annals of Internal Medicine, 2021, 174, ITC1-ITC16.	3.9	38
9	Mortality and Access to Kidney Transplantation in Patients with Sickle Cell Disease–Associated Kidney Failure. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 407-414.	4.5	14
10	Women with sickle cell disease report low knowledge and use of long acting reversible contraception. Journal of the National Medical Association, 2021, 113, 552-559.	0.8	9
11	Low rates of transfusionâ€ŧransmitted infection screening in chronically transfused adults with sickle cell disease. Transfusion, 2021, 61, 2421-2429.	1.6	1
12	Kneeling Was the First Step for Sickle Cell Disease. Annals of Internal Medicine, 2021, 174, 1004-1005.	3.9	4
13	Gaps in the diagnosis and management of iron overload in sickle cell disease: a â€ ⁻ realâ€world' report from the GRNDaD registry. British Journal of Haematology, 2021, 195, e157-e160.	2.5	4
14	A community-centered approach to sickle cell disease and clinical trial participation: an evaluation of perceptions, facilitators, and barriers. Blood Advances, 2021, 5, 5323-5331.	5.2	3
15	Treatment of Acute Pain in Adults With Sickle Cell Disease in an Infusion Center Versus the Emergency Department. Annals of Internal Medicine, 2021, 174, 1207-1213.	3.9	16
16	Swaying sickle cell research forward in support of patient reported outcomes. American Journal of Hematology, 2021, 96, 402-403.	4.1	1
17	Innovations in Targeted Antiâ€Adhesion Treatment for Sickle Cell Disease. Clinical Pharmacology and Therapeutics, 2020, 107, 140-146.	4.7	4
18	Marijuana use and health behaviors in a US clinic sample of patients with sickle cell disease. PLoS ONE, 2020. 15. e0235192.	2.5	3

#	Article	IF	CITATIONS
19	Comparison of US Federal and Foundation Funding of Research for Sickle Cell Disease and Cystic Fibrosis and Factors Associated With Research Productivity. JAMA Network Open, 2020, 3, e201737.	5.9	102
20	Hydroxycarbamide exposure and ovarian reserve in women with sickle cell disease in the Multicenter Study of Hydroxycarbamide. British Journal of Haematology, 2020, 191, 880-887.	2.5	25
21	The Economic Burden of End-Organ Damage Among Medicaid Patients with Sickle Cell Disease in the United States: A Population-Based Longitudinal Claims Study. Journal of Managed Care & Specialty Pharmacy, 2020, 26, 1121-1129.	0.9	11
22	Psychosocial and Clinical Risk Factors Associated with Substance Use in Observational Cohort of Patients with Sickle Cell Disease. Substance Use and Misuse, 2020, 55, 2205-2212.	1.4	5
23	Building access to care in adult sickle cell disease: defining models of care, essential components, and economic aspects. Blood Advances, 2020, 4, 3804-3813.	5.2	57
24	Quality Metrics and Health Care Utilization for Adult Patients with Sickle Cell Disease. Journal of the National Medical Association, 2019, 111, 54-61.	0.8	7
25	The Role of Patient-Physician Communication on the Use of Hydroxyurea in Adult Patients with Sickle Cell Disease. Journal of Racial and Ethnic Health Disparities, 2019, 6, 1233-1243.	3.2	6
26	National trends in hydroxyurea and opioid prescribing for sickle cell disease by officeâ€based physicians in the United States, 1997â€2017. Pharmacoepidemiology and Drug Safety, 2019, 28, 1246-1250.	1.9	25
27	Estimated Life Expectancy and Income of Patients With Sickle Cell Disease Compared With Those Without Sickle Cell Disease. JAMA Network Open, 2019, 2, e1915374.	5.9	163
28	Overcoming challenges of venous thromboembolism in sickle cell disease treatment. Expert Review of Hematology, 2019, 12, 173-182.	2.2	11
29	American Society of Hematology 2019 guidelines for sickle cell disease: cardiopulmonary and kidney disease. Blood Advances, 2019, 3, 3867-3897.	5.2	87
30	2019 sickle cell disease guidelines by the American Society of Hematology: methodology, challenges, and innovations. Blood Advances, 2019, 3, 3945-3950.	5.2	14
31	Preliminary evidence that hydroxyurea is associated with attenuated peripheral sensitization in adults with sickle cell disease. Pain Reports, 2019, 4, e724.	2.7	5
32	Metabolic syndrome among adults living with sickle cell disease. Blood Cells, Molecules, and Diseases, 2019, 74, 25-29.	1.4	8
33	Clinical and Ophthalmic Factors Associated With the Severity of Sickle Cell Retinopathy. American Journal of Ophthalmology, 2019, 197, 105-113.	3.3	20
34	Do Words Matter? Stigmatizing Language and the Transmission of Bias in the Medical Record. Journal of General Internal Medicine, 2018, 33, 685-691.	2.6	217
35	Daily Opioid Use Fluctuates as a Function of Pain, Catastrophizing, and Affect in Patients With Sickle Cell Disease: An Electronic Daily Diary Analysis. Journal of Pain, 2018, 19, 46-56.	1.4	39
36	Transition to adulthood and adult health care for patients with sickle cell disease or cystic fibrosis: Current practices and research priorities. Journal of Clinical and Translational Science, 2018, 2, 334-342.	0.6	28

#	Article	IF	CITATIONS
37	Risks associated with fertility preservation for women with sickle cell anemia. Fertility and Sterility, 2018, 110, 720-731.	1.0	28
38	A prospective quality improvement initiative in adult hemophagocytic lymphohistiocytosis to improve testing and a framework to facilitate trigger identification and mitigate hemorrhage from retrospective analysis. Medicine (United States), 2018, 97, e11579.	1.0	20
39	Increased acute care utilization in a prospective cohort of adults with sickle cell disease. Blood Advances, 2018, 2, 2412-2417.	5.2	31
40	A Phase 3 Trial of <scp>l</scp> -Glutamine in Sickle Cell Disease. New England Journal of Medicine, 2018, 379, 226-235.	27.0	378
41	Challenges in the management of the transgender patient with sickle cell disease. American Journal of Hematology, 2018, 93, E360-E362.	4.1	7
42	Predictors of acute care utilization and acute pain treatment outcomes in adults with sickle cell disease: The role of nonâ€hematologic characteristics and baseline chronic opioid dose. American Journal of Hematology, 2018, 93, 1127-1135.	4.1	18
43	Assessing the Safety and Efficacy of Converting Adults with Sickle Cell Disease from Full Agonist Opioids to Buprenorphine. Blood, 2018, 132, 856-856.	1.4	5
44	Societal Costs of Sickle Cell Disease in the United States. Blood, 2018, 132, 4706-4706.	1.4	2
45	Iron Overload Is Under-Recognized and Under-Treated in SCD: A Report from the Grndad Registry. Blood, 2018, 132, 158-158.	1.4	0
46	Modifiable Cardiovascular Risk Factors in Adults with Sickle Cell Disease. Blood, 2018, 132, 1088-1088.	1.4	2
47	Patient Satisfaction of Care in the Treatment of Vaso-Occlusive Crises: A Comparison of Emergency Department and Infusion Centers in the Escaped Study. Blood, 2018, 132, 314-314.	1.4	0
48	A Five Fold Decrease in Admissions for Uncomplicated Vaso-Occlusive Crisis and Other Benefits from Care in Infusion Clinics: Results from the Escaped Trial. Blood, 2018, 132, 853-853.	1.4	1
49	Negative studies shape the state of sickle trait. Blood, 2017, 129, 661-662.	1.4	2
50	Efficacy and Safety of Ledipasvir/Sofosbuvir for the Treatment of Chronic Hepatitis C in Persons With Sickle Cell Disease. Clinical Infectious Diseases, 2017, 65, 864-866.	5.8	9
51	Look into my eyes: An unusual first presentation of sickle cell disease. American Journal of Hematology, 2017, 92, 968-971.	4.1	2
52	Developmental Outcomes of Children Exposed to Maternal Sickle Cell Disease (SCD). Blood, 2017, 130, 983-983.	1.4	0
53	Effect of Free Dental Services on Individuals with Sickle Cell Disease. Southern Medical Journal, 2016, 109, 576-578.	0.7	5
54	Patent foramen ovale in adults with sickle cell disease and stroke. American Journal of Hematology, 2016, 91, E358-60.	4.1	4

4

#	Article	IF	CITATIONS
55	Improving Emergency Providers' Attitudes Toward Sickle Cell Patients in Pain. Journal of Pain and Symptom Management, 2016, 51, 628-632.e3.	1.2	25
56	Chronic Opioid Therapy and Central Sensitization in Sickle Cell Disease. American Journal of Preventive Medicine, 2016, 51, S69-S77.	3.0	65
57	Disease-Related, Nondisease-Related, and Situational Catastrophizing in Sickle Cell Disease and Its Relationship With Pain. Journal of Pain, 2016, 17, 1227-1236.	1.4	29
58	Pregnancy in Subjects with Hemoglobinopathies: Precautions and Management. , 2016, , 661-668.		0
59	Multiple Levels of Suffering. Clinical Journal of Pain, 2016, 32, 1076-1085.	1.9	52
60	Quantitative sensory testing and pain-evoked cytokine reactivity. Pain, 2016, 157, 949-956.	4.2	47
61	The Association between Educational Attainment and Patterns of Emergency Department Utilization among Adults with Sickle Cell Disease. International Journal of Behavioral Medicine, 2016, 23, 300-309.	1.7	16
62	The Measure of Sickle Cell Stigma: Initial findings from the Improving Patient Outcomes through Respect and Trust study. Journal of Health Psychology, 2016, 21, 808-820.	2.3	53
63	An Evaluation of Central Sensitization in Patients With Sickle Cell Disease. Journal of Pain, 2016, 17, 617-627.	1.4	79
64	Risk factors for venous thromboembolism in adults with hemoglobin SC or Sβ+ thalassemia genotypes. Thrombosis Research, 2016, 141, 35-38.	1.7	22
65	Acute Care Utilization Is More Common in Patients with Sickle Cell Disease Who Have Chronic Complications and Chronic Pain: A Preliminary Report from the Escaped Trial. Blood, 2016, 128, 2490-2490.	1.4	1
66	Improving Inpatient Care for Individuals with Sickle Cell Disease Using the Project ECHO Model. Southern Medical Journal, 2016, 109, 568-569.	0.7	3
67	Utility of the Montreal Cognitive Assessment as a Screening Test for Neurocognitive Dysfunction in Adults with Sickle Cell Disease. Southern Medical Journal, 2016, 109, 560-565.	0.7	10
68	Symptomatic Avascular Necrosis: An Understudied Risk Factor for Acute Care Utilization by Patients with SCD. Southern Medical Journal, 2016, 109, 519-524.	0.7	8
69	Need for Specialized Centers to Provide Acute Care to Adults with Sickle Cell Disease. Southern Medical Journal, 2016, 109, 566-567.	0.7	5
70	Hospitalization for Acute Pain in Sickle Cell Disease: Changes in Clinical Parameters and Factors Predicting Hospital Discharge and Re-Admission. Blood, 2016, 128, 3662-3662.	1.4	0
71	The five key things you need to know to manage adult patients with sickle cell disease. Hematology American Society of Hematology Education Program, 2015, 2015, 420-425.	2.5	9
72	Evidence gaps in the management of sickle cell disease: A summary of needed research. American Journal of Hematology, 2015, 90, 273-275.	4.1	37

#	Article	IF	CITATIONS
73	Randomized phase 2 study of GMI-1070 in SCD: reduction in time to resolution of vaso-occlusive events and decreased opioid use. Blood, 2015, 125, 2656-2664.	1.4	178
74	The Association of Clinician Characteristics with their Attitudes Toward Patients with Sickle Cell Disease: Secondary Analyses of a Randomized Controlled Trial. Journal of the National Medical Association, 2015, 107, 89-96.	0.8	13
75	Quality Improvement Process in a Sickle Cell Infusion Center. American Journal of Medicine, 2015, 128, 541-544.	1.5	9
76	Impact of a dedicated infusion clinic for acute management of adults with sickle cell pain crisis. American Journal of Hematology, 2015, 90, 376-380.	4.1	43
77	Metabolic Syndrome Risk Among Adults Living with Sickle Cell Disease. Blood, 2015, 126, 3405-3405.	1.4	1
78	Primary Care Providers' Comfort Levels in Caring for Patients with Sickle Cell Disease. Southern Medical Journal, 2015, 108, 531-536.	0.7	28
79	Management of Sickle Cell Disease. JAMA - Journal of the American Medical Association, 2014, 312, 1033.	7.4	1,189
80	Perceived Discrimination, Patient Trust, and Adherence to Medical Recommendations Among Persons with Sickle Cell Disease. Journal of General Internal Medicine, 2014, 29, 1657-1662.	2.6	96
81	Practice Guideline for Pulmonary Hypertension in Sickle Cell: Direct Evidence Needed before Universal Adoption. American Journal of Respiratory and Critical Care Medicine, 2014, 190, 237-238.	5.6	1
82	Association of Sickle Cell Trait With Chronic Kidney Disease and Albuminuria in African Americans. JAMA - Journal of the American Medical Association, 2014, 312, 2115.	7.4	167
83	Venous thromboembolism incidence in the Cooperative Study of Sickle Cell Disease. Journal of Thrombosis and Haemostasis, 2014, 12, 2010-2016.	3.8	123
84	Perceived Discrimination in Health Care Is Associated With a Greater Burden of Pain in Sickle Cell Disease. Journal of Pain and Symptom Management, 2014, 48, 934-943.	1.2	91
85	Vasculopathy, inflammation, and blood flow in leg ulcers of patients with sickle cell anemia. American Journal of Hematology, 2014, 89, 1-6.	4.1	62
86	Attitudes toward clinical trials among patients with sickle cell disease. Clinical Trials, 2014, 11, 275-283.	1.6	17
87	An unequal burden: Poor patient–provider communication and sickle cell disease. Patient Education and Counseling, 2014, 96, 159-164.	2.2	37
88	Screening for Neurocognitive Dysfunction in an Adult Population with Sickle Cell Disease. Blood, 2014, 124, 2717-2717.	1.4	5
89	Successful Use of Pegylated Carboxyhemoglobin Bovine As an Emergency Treatment for Severe Anemia in a Patient with Sickle Cell Disease and Hyperhemolysis: A Case Report. Blood, 2014, 124, 4928-4928.	1.4	2
90	Risk Factors for Death in 632 Patients with Sickle Cell Disease in the United States and United Kingdom. PLoS ONE, 2014, 9, e99489.	2.5	107

6

#	Article	IF	CITATIONS
91	Patent Foramen Ovale in Adult Patients with Sickle Cell Disease and Stroke. Blood, 2014, 124, 4084-4084.	1.4	Ο
92	Essential Thrombocytosis: Redefinition in the Genomic Era. Blood, 2014, 124, 3205-3205.	1.4	0
93	Avascular Necrosis: An Understudied Risk Factor for Acute Care Utilization By Patients with Sickle Cell Disease. Blood, 2014, 124, 2709-2709.	1.4	Ο
94	An Analysis of VTE Prophylaxis Practice in Oncology Patients after Implementation of a Standardized Mandatory Computerized Clinical Decision Support Tool. Blood, 2014, 124, 4859-4859.	1.4	0
95	Sickle cell disease and venous thromboembolism: what the anticoagulation expert needs to know. Journal of Thrombosis and Thrombolysis, 2013, 35, 352-358.	2.1	79
96	Venous Thromboembolism in Adults with Sickle Cell Disease: A Serious and Under-recognized Complication. American Journal of Medicine, 2013, 126, 443-449.	1.5	156
97	The impact of race and disease on sickle cell patient wait times in the emergency department. American Journal of Emergency Medicine, 2013, 31, 651-656.	1.6	98
98	The Reply. American Journal of Medicine, 2013, 126, e15.	1.5	0
99	Evaluation of a Train-the-Trainer Workshop on Sickle Cell Disease for ED Providers. Journal of Emergency Nursing, 2013, 39, 539-546.	1.0	10
100	Patent Foramen Ovale in Patients with Sickle Cell Disease and Stroke: Case Presentations and Review of the Literature. Case Reports in Hematology, 2013, 2013, 1-5.	0.4	11
101	The relationship between the severity of hemolysis, clinical manifestations and risk of death in 415 patients with sickle cell anemia in the US and Europe. Haematologica, 2013, 98, 464-472.	3.5	170
102	Mortality Rates and Age at Death from Sickle Cell Disease: U.S., 1979–2005. Public Health Reports, 2013, 128, 110-116.	2.5	354
103	A Preliminary Study of Psychiatric, Familial, and Medical Characteristics of High-utilizing Sickle Cell Disease Patients. Clinical Journal of Pain, 2013, 29, 317-323.	1.9	33
104	Cost Benefit Analysis Of a Sickle Cell Infusion Center For The Treatment Of Vaso-Occlusive Crises. Blood, 2013, 122, 1697-1697.	1.4	1
105	Perceived Discrimination In Health Care Is Associated With Daily Chronic Pain In Sickle Cell Disease. Blood, 2013, 122, 5577-5577.	1.4	1
106	Effects Of GMI 1070, a Pan-Selectin Inhibitor, On Pain Intensity and Opioid Utilization In Sickle Cell Disease. Blood, 2013, 122, 775-775.	1.4	2
107	GMI 1070: Reduction In Time To Resolution Of Vaso-Occlusive Crisis and Decreased Opioid Use In a Prospective, Randomized, Multi-Center Double Blind, Adaptive Phase 2 Study In Sickle Cell Disease. Blood, 2013, 122, 776-776.	1.4	7
108	Venous Thromboembolism Incidence In The Cooperative Study Of Sickle Cell Disease: The Untold Story. Blood, 2013, 122, 2214-2214.	1.4	0

#	Article	IF	CITATIONS
109	Baby on board: what you need to know about pregnancy in the hemoglobinopathies. Hematology American Society of Hematology Education Program, 2012, 2012, 208-214.	2.5	25
110	Describing Adherence to Recommended Preventative Care Behaviors Among Adults with Sickle Cell Disease. Blood, 2012, 120, 2058-2058.	1.4	0
111	Polycythemia Vera: Redefinition in the Genomic Era. Blood, 2012, 120, 1754-1754.	1.4	0
112	Higher Baseline Hemoglobin and Splenectomy Are Risk Factors for Venous Thromboembolism in Adults with Sickle Cell Variant Genotypes. Blood, 2012, 120, 3243-3243.	1.4	0
113	Baby on board: what you need to know about pregnancy in the hemoglobinopathies. Hematology American Society of Hematology Education Program, 2012, 2012, 208-14.	2.5	18
114	Hospitalization for pain in patients with sickle cell disease treated with sildenafil for elevated TRV and low exercise capacity. Blood, 2011, 118, 855-864.	1.4	210
115	Religious coping and hospital admissions among adults with sickle cell disease. Journal of Behavioral Medicine, 2011, 34, 120-127.	2.1	31
116	A Video-Intervention to Improve Clinician Attitudes Toward Patients with Sickle Cell Disease: The Results of a Randomized Experiment. Journal of General Internal Medicine, 2011, 26, 518-523.	2.6	68
117	Prediction of onset and course of high hospital utilization in sickle cell disease. Journal of Hospital Medicine, 2011, 6, 248-255.	1.4	48
118	Examining the characteristics and beliefs of hydroxyurea users and nonusers among adults with sickle cell disease. American Journal of Hematology, 2011, 86, 85-87.	4.1	50
119	Nitric Oxide for Inhalation in the Acute Treatment of Sickle Cell Pain Crisis. JAMA - Journal of the American Medical Association, 2011, 305, 893.	7.4	196
120	Echocardiographic Markers of Elevated Pulmonary Pressure and Left Ventricular Diastolic Dysfunction Are Associated With Exercise Intolerance in Adults and Adolescents With Homozygous Sickle Cell Anemia in the United States and United Kingdom. Circulation, 2011, 124, 1452-1460.	1.6	124
121	The epidemiology, evaluation and treatment of stroke in adults with sickle cell disease. Expert Review of Hematology, 2011, 4, 597-606.	2.2	70
122	Do Sickle Cell Patients Wait Longer to See Physicians in the Emergency Department?. Blood, 2011, 118, 2070-2070.	1.4	2
123	Trends In the Hospital Treatment of Sickle Cell Disease-Related Priapism In the United States: 1998 to 2007,. Blood, 2011, 118, 4195-4195.	1.4	1
124	Non-Cardiopulmonary Factors Affecting the Six-Minute Walk Distance in Patients with Sickle Cell Disease: Results From the Walk-PHaSST Study. Blood, 2011, 118, 1074-1074.	1.4	1
125	The Association of Provider Communication with Trust among Adults with Sickle Cell Disease. Journal of General Internal Medicine, 2010, 25, 543-548.	2.6	71
126	The burden of emergency department use for sickleâ€cell disease: An analysis of the national emergency department sample database. American Journal of Hematology, 2010, 85, 797-799.	4.1	176

#	Article	IF	CITATIONS
127	Hospital self-discharge among adults with sickle-cell disease (SCD): Associations with trust and interpersonal experiences with care. Journal of Hospital Medicine, 2010, 5, 289-294.	1.4	46
128	Examining the Effectiveness of Hydroxyurea in People with Sickle Cell Disease. Journal of Health Care for the Poor and Underserved, 2010, 21, 277-286.	0.8	24
129	Time to Recognize an Overlooked Trait. Journal of the American Society of Nephrology: JASN, 2010, 21, 385-386.	6.1	5
130	Problematic Hospital Experiences among Adult Patients with Sickle Cell Disease. Journal of Health Care for the Poor and Underserved, 2010, 21, 1114-1123.	0.8	51
131	NT-Probnp as a Marker of Cardiopulmonary Compromise and Exercise Limitation In Adults with Sickle Cell Anemia In the Walk-PHaSST Study. Blood, 2010, 116, 1639-1639.	1.4	0
132	Predictors of Six-Minute Walk Distance In Adults with Sickle Cell Anemia In the Walk-PHaSST Study. Blood, 2010, 116, 947-947.	1.4	1
133	Chronic Pain Is An Independent Predictor of Lower 6 Minute Walk Distance In Patients with Sickle Cell Disease: Results From Walk-PHaSST Study. Blood, 2010, 116, 2658-2658.	1.4	0
134	Trends In Mortality Rates and Age of Death In Sickle Cell Disease (SCD): 1979–2005. Blood, 2010, 116, 736-736.	1.4	0
135	Cigarette Smoking Is An Independent Predictor of Chronic Pain In Sickle Cell Patients: Results From the Walk-PHaSST Study. Blood, 2010, 116, 4804-4804.	1.4	0
136	A Systematic Review of Barriers and Interventions to Improve Appropriate Use of Therapies for Sickle Cell Disease. Journal of the National Medical Association, 2009, 101, 1022-1033.	0.8	135
137	The excess burden of stroke in hospitalized adults with sickle cell disease. American Journal of Hematology, 2009, 84, 548-552.	4.1	75
138	The course and correlates of high hospital utilization in sickle cell disease: Evidence from a large, urban Medicaid managed care organization. American Journal of Hematology, 2009, 84, 666-670.	4.1	112
139	Health care provider attitudes toward patients with acute vaso-occlusive crisis due to sickle cell disease: Development of a scale. Patient Education and Counseling, 2009, 76, 272-278.	2.2	55
140	Hydroxyurea for Sickle Cell Disease: A Systematic Review for Efficacy and Toxicity in Children. Pediatrics, 2008, 122, 1332-1342.	2.1	189
141	Provider Barriers to Hydroxyurea Use in Adults with Sickle Cell Disease: A Survey of the Sickle Cell Disease Adult Provider Network. Journal of the National Medical Association, 2008, 100, 968.	0.8	44
142	Provider Barriers to Hydroxyurea Use in Adults with Sickle Cell Disease: A Survey of the Sickle Cell Disease Adult Provider Network. Journal of the National Medical Association, 2008, 100, 968-974.	0.8	99
143	Systematic Review: Hydroxyurea for the Treatment of Adults with Sickle Cell Disease. Annals of Internal Medicine, 2008, 148, 939.	3.9	224
144	Provider barriers to hydroxyurea use in adults with sickle cell disease: a survey of the Sickle Cell Disease Adult Provider Network. Journal of the National Medical Association, 2008, 100, 968-73.	0.8	44

#	Article	IF	CITATIONS
145	Predictors of In-Hospital Mortality and Charges in Sickle Cell Disease: Results from the California Discharge Databases 1998–2005 Blood, 2007, 110, 432-432.	1.4	1
146	Sickle Cell Disease Mortality in the United States: Age at Death and Contributing Causes Blood, 2007, 110, 81-81.	1.4	6
147	Risk Factors for Primary Hemorrhagic Stroke in Adults with Sickle Cell Disease Blood, 2007, 110, 3809-3809.	1.4	Ο
148	Documenting the Effectiveness of Hydroxyurea (HU) To Treat Sickle Cell Disease (SCD) in the Community Setting Blood, 2007, 110, 956-956.	1.4	0
149	Self-perceived Loss of Control and Untreated Dental Decay in African American Adults With and Without Sickle Cell Disease. Journal of Health Care for the Poor and Underserved, 2006, 17, 641-651.	0.8	7
150	The association between sickle cell disease and dental caries in African Americans. Special Care in Dentistry, 2006, 26, 95-100.	0.8	47
151	High prevalence and correlates of low bone mineral density in young adults with sickle cell disease. American Journal of Hematology, 2006, 81, 236-241.	4.1	100
152	Hospitalization rates and costs of care of patients with sickle-cell anemia in the state of Maryland in the era of hydroxyurea. American Journal of Hematology, 2006, 81, 927-932.	4.1	140
153	Experience of Respect and Pain Management among Adult Patients with Sickle Cell Disease during Vaso-Occlusive Crisis Blood, 2006, 108, 3341-3341.	1.4	Ο
154	Hospitalization Rates in Patients with Sickle Cell Disease (SCD) in the State of Maryland (MD): No Change Since Approval of Hydroxyurea (HU) Blood, 2004, 104, 107-107.	1.4	5
155	Polymerized human Hb use in acute chest syndrome: a case report. Transfusion, 2002, 42, 1422-1427.	1.6	36
156	Graft failure in a patient with systemic lupus erythematosus (SLE) treated with high-dose immunosuppression and autologous stem cell rescue. Bone Marrow Transplantation, 2001, 27, 221-224.	2.4	15
157	Homing of Long-Term and Short-Term Engrafting Cells In Vivoa. Annals of the New York Academy of Sciences, 1999, 872, 48-56.	3.8	26
158	Ex-vivo expansion of bone marrow progenitor cells for hematopoietic reconstitution following high-dose chemotherapy for breast cancer. Experimental Hematology, 1999, 27, 615-623.	0.4	55